Filing Flows › Alnylam Pharmaceuticals (ALNY) › Q2 2026
Alnylam Pharmaceuticals (ALNY) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 30, 2026
Alnylam Pharmaceuticals (ALNY) reported revenue of $1.3B for the second quarter 2026 (Q2 2026), +67% from a year earlier. Operating margin was 17.9%, net earnings $164M (12.7% of revenue).
Alnylam Pharmaceuticals, Q2 2026: revenue $1.3B (+67% year over year), operating margin 17.9%, net earnings $164M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3B | — | +67% |
| Operating profit | $231M | — | — |
| Net earnings | $164M | — | — |
What changed
Revenue was $1.3B in Q2 2026, up 67% year over year. AMVUTTRA was the largest line at 78% of revenue. AMVUTTRA added $0.52B year over year (up 106%), 100% of the total change. ONPATTRO declined 65%.
Operating profit was $0.23B, a 17.9% margin (up 20.0 points year over year). Total costs grew 34% against revenue growth of 67%. The fastest-growing cost line was Cost of revenue (+110%). Net earnings were $0.16B. The effective tax rate was 7.5%.
Questions
What was Alnylam Pharmaceuticals' revenue in the second quarter 2026?
Alnylam Pharmaceuticals (ALNY) reported revenue of $1.3B for the second quarter 2026 (Q2 2026), +67% from a year earlier.
Was Alnylam Pharmaceuticals profitable in the second quarter 2026?
Operating profit was $231M (17.9% of revenue) and net earnings $164M.